Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer Announces
The Phase 3 RESET trial testing the effectiveness and safety of rivipansel (GMI-1070), Pfizer‘s investigational candidate to treat vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease (SCD), failed to reach both its primary and secondary goals, top-line study results show.
“We are disappointed with the results, as we have been working in close partnership with the SCD community to advance rivipansel as a potential treatment option for acute VOC,” Brenda Cooperstone, MD, senior vice president and chief development officer, Rare Disease, Pfizer Global Product Development, said in a press release.
“We plan to share the study data at an upcoming scientific meeting as we want to ensure the learnings from this trial help inform future sickle cell programs,” Cooperstone added. “We express our sincere gratitude to everyone who made this study possible, including the study investigators, and in particular, the patients and their families.”
VOC, characterized by a reduced blood flow and ultimate closing of blood vessels due to the adhesion of sickle cells to vessel walls, is a serious complication of SCD linked with severe pain. Currently, VOC symptoms are managed with analgesics, including opioids and non-steroidal anti-inflammatory drugs (NSAIDs), but more effective therapies are needed.
+myBinderRelated Content
-
Sickle Cell Treatments can Destroy Germ Cells in Boys, Affecting Fertility in Adulthood, Study SuggestsSome treatments for sickle cell disease ...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
-
A randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for re...AIM: To test feasibility of a guided aud...
-
MARAC Statement: Crizanlizumab (Adakveo)July 7, 2023 - SCDAA’s Medical and Res...
-
Stigma and pain in adolescents hospitalized for sickle cell vasoocclusive pain episodesOBJECTIVES: Sickle cell disease (SCD) p...
-
The Bad Blood: My Life With Sickle Cell AnaemiaI wake up with an active volcano for a c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.